Pharmacologic class (EPC) · 8 drug pages

P2Y12 platelet inhibitor: adverse event reports filed with FDA

99,787 reports list a drug in this class as a suspect or interacting product, 2004–2026.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

99,787
reports across the class: 0.5% of all reports; 3,655
reports, 12 months to June 2026: 4,225 in the 12 months before; 88.3%
marked serious by the reporter: 57.4% across all reports; 8
drugs with a page: brand and generic names counted separately

P2Y12 platelet inhibitor is a pharmacologic class (an FDA Established Pharmacologic Class) with 8 drug pages on this site. Together those drugs are listed as a suspect or interacting product in 99,787 adverse event reports received by FDA, 0.5% of the database, from January 2004 to June 2026.

3,655 reports arrived in the 12 months to June 2026, down 13% from 4,225 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. 88.3% of the class's reports are marked serious, 12.9% record death among the outcomes and 46.9% record hospitalisation, as reported.

Across the class the reactions recorded most often are gastrointestinal haemorrhage (8.6%), dyspnoea (6.5%) and anaemia (4.7%). The class median share shown beside each term is the middle value across the member drugs; it is the comparison used on every drug page in this class.

The members table is ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Drugs in the class

Drug	Name type	Reports	Latest 12 months	Marked serious	Top term recorded
PlavixClopidogrel	brand	31,050	346	91.6%	Gastrointestinal haemorrhage
Clopidogrel	generic	29,816	1,800	95.6%	Anaemia
BrilintaTicagrelor	brand	17,760	210	67.5%	Dyspnoea
Clopidogrel bisulfate	generic	6,901	370	96%	Anaemia
Ticagrelor	generic	6,168	806	97.8%	Drug interaction
EffientPrasugrel hydrochloride	brand	5,820	45	75.1%	Gastrointestinal haemorrhage
Prasugrel hydrochloride	generic	1,295	16	95.5%	Vascular stent thrombosis
Prasugrel	generic	977	62	91.2%	Drug ineffective

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Reactions recorded across the class

share of class reports recording the termmedian drug in the class

Gastrointestinal haemorrhagebleeding in the stomach or bowel8.6%8,546
Dyspnoeashortness of breath6.5%6,524
Anaemialow red blood cells4.7%4,711
Myocardial infarctionheart attack4.5%4,456
Drug interactionan interaction between medicines4.4%4,402
Haemorrhagebleeding4.2%4,163
Deaththe patient died; cause not stated by this term3.3%3,294
Fatiguetiredness3.3%3,260
Dizzinesslight-headedness or unsteadiness3.2%3,209
Contusiona bruise3.1%3,050
Epistaxisnosebleed3%3,013
Drug ineffectivethe medicine did not work as expected3%2,960
Off label useused for a purpose or in a way not on the label2.9%2,885
Chest painchest pain2.8%2,814
Astheniaweakness or lack of energy2.7%2,703
Cerebral haemorrhage2.5%2,511
Nauseafeeling sick2.4%2,386
Cerebrovascular accidentstroke2.4%2,367
Melaenablack tarry stools2.3%2,301
Falla fall2.3%2,285
Haemoglobin decreasedlow haemoglobin2.1%2,112
Headachehead pain2.1%2,095
Rectal haemorrhage2%2,021
Malaisegeneral feeling of being unwell2%1,971
Diarrhoealoose or frequent stools2%1,948

Solid bar: share of all class reports. Hollow bar: the median share across the 8 member drugs, the reference used on each member's page. One report can record several terms.

Outcomes, patients and reporters

Outcomes recorded

Death12.9%12,899

Life-threatening7.8%7,811

Hospitalisation (initial or prolonged)46.9%46,757

Disability2.5%2,459

Congenital anomaly0.1%53

Other serious50.1%49,994

Not serious11.7%11,684

Patient age

Under 20.1%91

2 to 110.1%82

12 to 170.1%92

18 to 442.5%2,535

45 to 6420.1%20,051

65 to 7420.8%20,727

75 and over25%24,933

Age not given31.3%31,276

Who reported

Physician28.2%28,094

Pharmacist8.5%8,528

Other health professional20.5%20,421

Lawyer0.4%425

Consumer or non-health professional37.4%37,280

Not given5%5,039

Grey bar: all 20,646,523 reports in the database. Outcome flags are as the reporter set them and are not verified by FDA.

Questions about P2Y12 platelet inhibitor reports

Which drugs are in the P2Y12 platelet inhibitor class on this site?

Plavix, Clopidogrel, Brilinta, Clopidogrel bisulfate, Ticagrelor and Effient and 2 more. Class membership comes from the pharmacologic class (EPC) on the drug's FDA label.

How many reports does the class have?

99,787 reports through June 2026, 3,655 of them in the latest 12 months. A report listing two drugs of the class counts once for each.

What reactions are recorded most often?

gastrointestinal haemorrhage (8.6%), dyspnoea (6.5%), anaemia (4.7%), myocardial infarction (4.5%) and drug interaction (4.4%).

Can the members table be used to rank the drugs?

No. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." Drugs differ in how many people take them, in the conditions they treat, in time on the market and in how diligently reports are collected.

How do I report an adverse event?

Through FDA MedWatch (Form FDA 3500, or 1-800-FDA-1088) or to the manufacturer. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A class is the Established Pharmacologic Class most often attached to a drug's reports by openFDA's label harmonisation, or from the NDC Directory where reports carry none. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.